Virax Biolabs Group Ltd (VRAX) Cash & Equivalents (2021 - 2023)

Virax Biolabs (VRAX) has 3 years of Cash & Equivalents data on file, last reported at $9.4 million in Q1 2023.

• In Q1 2023, Cash & Equivalents rose 42888.32% year-over-year to $9.4 million; the TTM figure through Mar 2023 stood at $9.4 million (up 42888.32% YoY), while the FY2023 annual figure was $9.4 million, up 42888.32% from the prior year.
• Cash & Equivalents improved to $9.4 million in Q1 2023, from $21756.0 in the prior quarter.
• Across five years, Cash & Equivalents topped out at $9.4 million in Q1 2023 and bottomed at $17621.0 in Q1 2021.
• A 3-year average of $3.1 million and a median of $21756.0 in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents advanced 23.47% — and 2023, when it soared 42888.32%.
• Year by year, Cash & Equivalents stood at $17621.0 in 2021, then grew by 23.47% to $21756.0 in 2022, then soared by 42888.32% to $9.4 million in 2023.
• The last three Cash & Equivalents figures came in at $9.4 million (Q1 2023), $21756.0 (Q1 2022), and $17621.0 (Q1 2021), per Business Quant data.

Peer Comparison